Junshengtai Pharmaceuticals passed the Hong Kong Stock Exchange Listing Act 2023 R & D costs of 120 million yuan in the first half of the year

  • 内容
  • 评论
  • 相关


Viewpoint News:On December 10,moment information HighTide Therapeutics (Inc.) listed on the Hong Kong Stock Exchange.

According to the new media, Junshengtai Pharmaceutical was established in 2011. It is a biopharmaceutical company. It focuses on the discovery, development and commercialization multi -functional and multi -target therapy of the treatment of metabolic and digestive system diseases.1 core product and 4 other candidate products product pipelines.

The core product of Junshengtai Pharmaceutical HTD1801 (Little Bear Decolated Bile Acid) is a new molecular entity. As a anti -inflammatory and metabolic regulator, targeted regulation is vital to the human body's metabolism process.The pathway, including the pathway related to metabolic and digestive system diseases.

In the 6 months ended in 2021, 2022 and as of June 30, 2023, the cost of R & D costs of Junshengtai Pharmaceutical was RMB 84 million, RMB 183 million and RMB 120 million, respectively, accounting for 2021, 2022, respectively.62%, 81%, and 70%of the total operating expenses for the year ended June 30, 2023.

During the 6 months ended in 2021, 2022 and as of June 30, 2023, the R & D cost of the core product HTD1801 received RMB 76 million, RMB 174 million and RMB 114 million, respectively, respectively.90.5%, 95.1%, and 95.2%of the total R & D expenditure in 2021, 2022 and as of June 30, 2023.

Six months ended in 2021, 2022 and as of June 30, 2023, the amount of purchased from the five major R & D suppliers during each year/period was RMB 26.9 million, RMB 68.7 million and RMB.36.4 million yuan, accounting for 45.5%, 54.4%, and 45.7%of the corresponding total procurement of Junshengtai Pharmaceuticals, while Junshengtai Pharmaceuticals purchased from the largest R & D suppliers during each year/period, respectively.Total 12.0%, 17.9%and 26.5%. 

In addition, in May this year, Junshengtai Pharmaceutical submitted a listing application, and eventually suspended due to the expiration of more than 6 months.

On December 4, Junshengtai Pharmaceutical was delivered to the Hong Kong Stock Exchange for the second time.

版权声明:如非注明,此文章为本站原创文章,转载请注明: 转载自Express information website

本文链接地址: http://www.kjpartnersllc.com/post/20240213/33c594331.html